Overview

To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.

Status:
Completed
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
This Phase I study is a double-blind, randomized, placebo-controlled study designed to assess the safety, tolerability and PK profile of single intramuscular doses of DWRX2003 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.